We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Allergy Therapeutics
Innovative G309 exploratory grass trial startsFutura Medical
MED3000: FDA details the scope of confirmatory studyMereo BioPharma
H120 results and corporate reviewScancell
Redmile endorses technologies with a further £30mNexstim
Pilot studies lift off in depression and painAllergy Therapeutics
Strong performances against strategic goalsHutchison China MediTech
ESMO 2020: SANET-p delivers further positive suru dataMaxCyte
In the vanguard of next-generation cell and gene therapiesFutura Medical
MED3000 on course for OTC approval in Europe and USRedx Pharma
Proof is in the pipeline